Lupin Ltd Share Price Today

Lupin Ltd. Share Price

Overview

Lupin Ltd. share price is currently ₹2,065.30, up by ₹4.81 (0.23%) from its previous closing price of ₹2,060.49. The share price has declined -7.11% over the past month and gained 7.37% over the past year. The stock's 52-week low and high are ₹1,866.40 and ₹2,505.27, respectively. Lupin Ltd. has a market capitalisation of ₹ 96,480.00 Cr. The share price was last updated on 11 Sep 2026, 03:50 PM IST.

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 900% at ₹18/Share	17-Jul-2026	17-Jul-2026
DividendsFinal Dividend of 600% at ₹12/Share	25-Jul-2025	25-Jul-2025

Actions

Ex-Date

Record-Date

DividendsFinal Dividend of 900% at ₹18/Share

17-Jul-2026

DividendsFinal Dividend of 600% at ₹12/Share

25-Jul-2025

Mutual Fund Holder	Jul 26 Shares held	Aug 26 Shares held
HDFC Balanced Advantage Fund - Growth	56.86 Lac	56.86 Lac no change
HDFC Flexi Cap Fund - Growth	44.16 Lac	48.89 Lac (10.71%)
HDFC Large Cap Fund - Growth	46.16 Lac	46.16 Lac no change
Mirae Asset Large & Midcap Fund - Regular Plan - Growth	36.89 Lac	39.39 Lac (6.78%)
Mirae Asset Midcap Fund - Regular Plan - Growth	27.64 Lac	31.14 Lac (12.66%)

Mutual Fund Holder

Jul 26

Shares held

Aug 26

Shares held

HDFC Balanced Advantage Fund - Growth

56.86 Lac

no change

HDFC Flexi Cap Fund - Growth

44.16 Lac

48.89 Lac

(10.71%)

HDFC Large Cap Fund - Growth

46.16 Lac

no change

Mirae Asset Large & Midcap Fund - Regular Plan - Growth

36.89 Lac

39.39 Lac

(6.78%)

Mirae Asset Midcap Fund - Regular Plan - Growth

27.64 Lac

31.14 Lac

(12.66%)

Sarathi Research

7 Sep • 2:09 PM · SEBI-Registered Analyst

Lupin Gets USFDA Approval for Modafinil Tablets

LUPIN

Pharmaceutical company Lupin has received approval from the US Food and Drug Administration (USFDA) to market Modafinil tablets in the United States. The medicine is used to improve wakefulness in patients suffering from excessive sleepiness associated with narcolepsy, obstructive sleep apnoea and shift-work sleep disorder. The approval strengthens Lupin’s product portfolio in the important US pharmaceutical market. Modafinil is a generic medicine, and Lupin will manufacture and market the approved tablets in the US. The development comes as Indian pharmaceutical companies continue to expand their presence in the US through new generic drug approvals. The company has been regularly adding products to its US portfolio through regulatory approvals, helping diversify its international business. Lupin’s shares remained in focus following the announcement

AKANSHA JAIN

7 Sep • 1:28 PM · SEBI-Registered Analyst

Lupin combines strong operating momentum

Lupin is in focus after receiving USFDA approval for Modafinil Tablets USP in 100 mg and 200 mg strengths**, a generic version of Provigil used for excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift-work disorder. The reference product recorded estimated U.S. sales of **$70.7 million** in the 12 months ended July 2026. The approval adds to Lupin’s growing U.S. pipeline. In Q1 FY27, revenue rose **33.3% YoY to ₹8,217 crore while EBITDA increased 42.8% to ₹2,580 crore with EBITDA margin improving to 31.4%. U.S. sales grew **42.9% to ₹3,435 crore**, highlighting the importance of the market. Investors should track product launches, U.S. pricing pressure, regulatory developments and margin sustainability. Bottom Line: Lupin combines strong operating momentum with continued U.S. pipeline expansion, making execution and future launches key monitorables. Disclaimer:For educational purposes only. Not investment advice or a buy/sell recommendation. Investors should conduct their own research.

Pavan Rawat

7 Sep • 11:06 AM · SEBI-Registered Analyst

LUPIN IN FOCUS POST MODAFINIL TABLETS APPROVAL FROM USFDA

LUPIN

Lupin shares are likely to remain in focus on September 7 after the pharmaceutical company received approval from the United States Food and Drug Administration (USFDA) for its generic drug used to improve wakefulness in adults with excessive sleepiness. The company announced that it received USFDA approval for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg. The approved tablets have been determined to be bioequivalent to the reference listed drug (RLD), Provigil Tablets, marketed by Nuvo Pharmaceuticals (Ireland) DAC. Modafinil is indicated to improve wakefulness in adult patients experiencing excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). In August, Lupin's subsidiary VISUfarma B.V. entered into an exclusive licensing agreement with Visus Therapeutics, a subsidiary of Tenpoint Therapeutics, to commercialise, market, promote, distribute and sell YUVEZZI. Lupin shares touched a 52-week high of ₹2,530, and a 52-week low of ₹1,900.30. The stock is currently trading 16.56% below its 52-week high and 11.09% above its 52-week low. The company's market capitalisation stands at approximately ₹96,528.82 crore.

InvestAce Capital

7 Sep • 11:00 AM · SEBI-Registered Analyst

Lupin: USFDA Approval for Modafinil Tablets

LUPIN

is in focus after receiving approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Modafinil Tablets USP in 100 mg and 200 mg strengths. The tablets are bioequivalent to Provigil Tablets, the reference listed drug, and are indicated to improve wakefulness in adults suffering from excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. According to IQVIA data, the U.S. market for the reference product recorded estimated annual sales of approximately $70.7 million for the 12 months ended July 2026. The approval adds another product to Lupin’s U.S. pharmaceutical portfolio and provides the company with an opportunity to participate in this market following regulatory clearance. Lupin shares were trading marginally lower in early trade despite the approval, with the stock quoted around ₹2,106 at 9:27 a.m. on September 7. Investors will now track the commercial launch of the product and its contribution to Lupin’s U.S. business.

Finkhoz Roboadvisory Services

7 Sep • 8:16 AM · SEBI-Registered Analyst

Lupin: USFDA approval adds a positive trigger

LUPIN

is in focus after receiving USFDA approval for Modafinil Tablets USP 100 mg and 200 mg. The drug is bioequivalent to Provigil and is used to improve wakefulness in adults suffering from excessive sleepiness linked to narcolepsy, obstructive sleep apnea and shift-work disorder. The approval strengthens Lupin’s U.S. generics portfolio and provides another product opportunity in its CNS segment. The reference product, Provigil, had estimated U.S. annual sales of $70.7 million as of July 2026, indicating a meaningful addressable market, although actual revenue potential for Lupin will depend on pricing, competition and market share. The stock closed at ₹2,111 on September 4, down 1.12%, and remains about 16.6% below its 52-week high of ₹2,530. Investor takeaway: The approval is a positive near-term catalyst for Lupin, but investors should monitor the product’s commercial launch, competitive intensity and U.S. pricing before assuming a significant earnings impact.

Pavan Rawat

7 Sep • 6:48 AM · SEBI-Registered Analyst

Lupin Gains on USFDA Approval for Modafinil Tablets

LUPIN

Lupin is in focus after receiving USFDA approval for Modafinil Tablets USP 100 mg and 200 mg, expanding its product portfolio in the US market. The tablets are bioequivalent to Provigil, the reference listed drug. The approval is positive for Lupin’s US generics business and adds another product to its CNS portfolio. The company continues to strengthen its presence in the US through new product launches and regulatory approvals. Lupin also reported strong Q1 FY27 performance, with revenue rising 32% YoY to ₹8,276.89 crore and operating profit increasing 41.8% YoY to ₹2,449.53 crore. Net profit stood at ₹1,416.98 crore, up 16% YoY. With strong earnings growth and continued US product approvals, Lupin’s growth outlook remains positive. However, investors will monitor US pricing pressure, regulatory developments and margin sustainability in the coming quarters.

Lupin Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Lupin Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Lupin Ltd.?

What is the market cap of Lupin Ltd.?

Should I buy Lupin Ltd. stock now?

What is the 52 week high and low of Lupin Ltd.?

Is the Lupin Ltd. stock good to buy?

Is Lupin Ltd. a good buy for the long term?

Is Lupin Ltd. overvalued or undervalued?

What is the PE and PB ratio of Lupin Ltd.?